HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
about
Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysisSmall G proteins in the cardiovascular system: physiological and pathological aspectsStatins potently reduce the cytokine-mediated IL-6 release in SMC/MNC coculturesRhoA/Rho-kinase and vascular diseases: what is the link?Fluvastatin and fluvastatin extended release: a clinical and safety profile.Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment.Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertensionComparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.Statins inhibit Rho kinase activity in patients with atherosclerosis.Cardioprotective stress response in the human fetal heart.Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery.Mechanisms of statin-mediated inhibition of small G-protein function.Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice.Novel role of Cdc42 and RalA GTPases in TNF-α mediated secretion of CCL2.HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease.Pravastatin and clopidogrel combined inhibit intimal hyperplasia in a rat carotid endarterectomy model.Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis.
P2860
Q26851763-E4CE085C-2194-4158-8108-2DA9E138FCDCQ27010607-CDB05E84-A580-46E9-A0EA-4CC28A3E22CAQ30318772-CD4DAFD8-5032-49B5-9D87-60F1A7C8742FQ34378293-C265BDD8-2A9C-4A25-B978-7DA625D0B729Q35879055-D161ECE1-C2B4-4EE3-8C57-2049AF9AC190Q36163801-CC140E7A-BA89-4DAF-8A0B-E4F1758F51CEQ36754160-331D3D22-1B67-4B6C-89FF-30C273511768Q36964914-39889CC6-0760-4B9B-8816-36EF5063744BQ37170931-E777D8A4-DE11-476C-ABF4-093A9CD33292Q37279038-1506F6BE-8A31-47C6-9484-83AB3908F3BEQ37670066-50022A10-A41E-48FD-9F31-751E71D3A392Q37765899-828A46C9-94CB-47AB-8B58-8B8937290599Q40387534-616F151D-9DCC-4C6D-90B8-74066098E26FQ42131539-BFB67B5E-B25E-47A8-907F-661652A53CE2Q42954250-BEFC32EE-2C3E-4689-8041-527C3438CE53Q44633043-9B138194-5865-4BAC-B59E-FC427C311034Q46926295-36806404-25B5-4BC7-B84F-ED9862B1E962Q54533235-B22E2506-87C3-442E-8799-581E98AA1254
P2860
HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
HMG-CoA reductase inhibitors r ...... vascular smooth muscle cells.
@en
HMG-CoA reductase inhibitors r ...... vascular smooth muscle cells.
@nl
type
label
HMG-CoA reductase inhibitors r ...... vascular smooth muscle cells.
@en
HMG-CoA reductase inhibitors r ...... vascular smooth muscle cells.
@nl
prefLabel
HMG-CoA reductase inhibitors r ...... vascular smooth muscle cells.
@en
HMG-CoA reductase inhibitors r ...... vascular smooth muscle cells.
@nl
P2093
P356
P1476
HMG-CoA reductase inhibitors r ...... vascular smooth muscle cells.
@en
P2093
Kazuyuki Shimada
Keiji Yamamoto
Masafumi Takahashi
Masahisa Shimpo
Takayuki Ito
Uichi Ikeda
P304
P356
10.1023/A:1015701415588
P577
2002-03-01T00:00:00Z